First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSynnovation Therapeutics, Inc.
About this trial
This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.
Eligibility criteria
Qualifiers
Adults (18 years and older).
Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
Cancer confirmed by tissue or cell examination (histology or cytology).
At least one measurable tumor on scans.
Disqualifiers
Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.
Active, uncontrolled infections.
Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).
Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).
Trial design
Treatments tested in this trial
- SNV1521
- daraxonrasib
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Synnovation Therapeutics, Inc.
Lead sponsor
Revolution Medicines, Inc.
Collaborator
Source ClinicalTrials.gov